Scholarlink

Objective <p>Severe Fever with Thrombocytopenia Syndrome (SFTS), an emerging infectious disease of essential public health concern, currently lacks specific antiviral treatments, This study evaluated the efficacy of the broad-spectrum antiviral drug T-705 (Favipiravir).</p> Methods <p>Using propensity score matching (PSM) to minimize confounding factors between T-705 and Non-T-705 groups, Absolute Shrinkage and Selection Operator (LASSO) regression and multivariate logistic regression were used to screen the factors affecting the efficacy of T-705.</p> Results <p>Analysis revealed a consistently higher disease improvement rate in the T-705 group (82.3% Pre-PSM, 80.6% Post-PSM) compared to Non-T-705 group (67.3%), with the difference remaining statistically significant (<i>P</i> = 0.032) after PSM.</p> <p>The results demonstrated that Ct values (1.397, 1.168–1.671, <i>P</i> &lt; 0.001), lactate dehydrogenase (LDH) (1.002, 1.001–1.003, <i>P</i> = 0.027) and albumin (ALB) (1.153, 1.001–1.330, <i>P</i> = 0.050) levels were the protective factor for disease improvement, while clinical type (0.146, 0.045–0.477, <i>P</i> = 0.001), age (0.942, 0.893–0.994, <i>P</i> = 0.030), activated partial thromboplastin time (APTT) (0.917, 0.873–0.963, <i>P</i> &lt; 0.001), total bilirubin (TBIL) (0.867, 0.752–0.999, <i>P</i>= 0.048), creatinine (CREA) (0.992, 0.985–0.999, <i>P</i> = 0.038) and uric acid (UA) (0.994, 0.990–0.999, <i>P</i> = 0.017) levels were risk factors for disease improvement.</p> Conclusions <p>The study demonstrated that T-705 exhibited significant efficacy and favorable safety in the treatment of SFTS patients. Furthermore, a multivariate logistic regression verified its clinical significance, thereby providing robust evidence to support its inclusion in treatment guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of clinical efficacy and safety of T-705 (Favipiravir) in the treatment of fever with thrombocytopenia syndrome: a propensity score matching study

  • 期刊论文

  • 发表日期：

    2026年1月4日

查看全文
  • Fei Zhao,
  • Quanman Hu,
  • Anmin Ge,
  • Yan Hu,
  • Yanyan Yang,
  • Jundong Chen,
  • Saiwei Lu,
  • Yangfan Ou,
  • Wenyao Su,
  • Li Zhang,
  • Shuaiyin Chen

摘要

Objective

Severe Fever with Thrombocytopenia Syndrome (SFTS), an emerging infectious disease of essential public health concern, currently lacks specific antiviral treatments, This study evaluated the efficacy of the broad-spectrum antiviral drug T-705 (Favipiravir).

Methods

Using propensity score matching (PSM) to minimize confounding factors between T-705 and Non-T-705 groups, Absolute Shrinkage and Selection Operator (LASSO) regression and multivariate logistic regression were used to screen the factors affecting the efficacy of T-705.

Results

Analysis revealed a consistently higher disease improvement rate in the T-705 group (82.3% Pre-PSM, 80.6% Post-PSM) compared to Non-T-705 group (67.3%), with the difference remaining statistically significant (P = 0.032) after PSM.

The results demonstrated that Ct values (1.397, 1.168–1.671, P < 0.001), lactate dehydrogenase (LDH) (1.002, 1.001–1.003, P = 0.027) and albumin (ALB) (1.153, 1.001–1.330, P = 0.050) levels were the protective factor for disease improvement, while clinical type (0.146, 0.045–0.477, P = 0.001), age (0.942, 0.893–0.994, P = 0.030), activated partial thromboplastin time (APTT) (0.917, 0.873–0.963, P < 0.001), total bilirubin (TBIL) (0.867, 0.752–0.999, P= 0.048), creatinine (CREA) (0.992, 0.985–0.999, P = 0.038) and uric acid (UA) (0.994, 0.990–0.999, P = 0.017) levels were risk factors for disease improvement.

Conclusions

The study demonstrated that T-705 exhibited significant efficacy and favorable safety in the treatment of SFTS patients. Furthermore, a multivariate logistic regression verified its clinical significance, thereby providing robust evidence to support its inclusion in treatment guidelines.